News Headlines Article

With 365% stock climb, this Bay Area drug maker has skin in the game
San Francisco Business Times

Wall Street is scratching its health care itch, nearly quadrupling the value of Anacor Pharmaceuticals Inc.’s stock on the hopes of quick regulatory approval and a potential 2017 launch of the company’s late-stage eczema treatment. Much of the stock boom came this month, after Palo Alto-based Anacor (NASDAQ: ANAC) announced early data from two studies of crisaborole — formerly known as AN-2728 — in people with raised, red, itchy and oozing blotches also known as atopic dermatitis.